References
- Russell DW, Wilson JD. Steroid 5alpha-reductase: two genes/two enzymes. Ann Rev Biochem 1994;63:25–61
- Liang TEHM, Cascieri MA, Cheung AH, et al. Species differences in prostatic steroid 5α-reductases of rat, dog, and human. Endocrinology 1985;117:571–9
- Lee HJ, Chang C. Recent advances in androgen receptor action. Cell Mol Life Sci CMLS 2003;60:1613–22
- Shiba K, Hamaguchi T, Kataoka K, et al. Cloning of the hamster androgen receptor gene. J Dermatol Sci 2001;26:163–8
- Cabeza M, Heuze Y, Quintana H, Bratoeff E. Comparison between two different hamster models used for the determination of testosterone and finasteride activity. Asian J Anim Veter Adv 2010;5:202–9
- Trapani G, Dazzi L, Pisu MG, et al. A rapid method for obtaining finasteride, a 5α-reductase inhibitor, from commercial tablets. Brain Res Protocol 2002;9:130–4
- Njar VCO, Kato K, Nnane IP, et al. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-hydroxylase-C17,20-lyase (P45017α): potential agents for the treatment of prostate cancer. J Med Chem 1998;41:902–12
- Garrido M, Cabeza M, Cortés F, et al. Cytotoxic effect of novel dehydroepiandrosterone derivatives on different cancer cell lines. Eur J Med Chem 2013;68:301–11
- Hirosumi J, Nakayama O, Fagan T, et al. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (1) in vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol 1995;52:357–63
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54
- Levy MA, Brandt M, Greway AT. Mechanistic studies with solubilized rat liver steroid 5.alpha.-reductase: elucidation of the kinetic mechanism. Biochemistry 1990;29:2808–15
- Wright AS, Douglas RC, Thomas LN, et al. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology 1999;140:4509–15
- Bratoeff E, Ramírez E, Flores E, et al. Molecular interactions of new pregnenedione derivatives. Chem Pharmaceut Bull 2003;51:1132–6
- Machetti F, Guarna A. Novel inhibitors of 5α-reductase. Expert Opin Therapeut Patents 2002;12:201–15
- Thomas LN, Douglas RC, Lazier CB, et al. Type 1 and Type 2 5α-reductase expression in the development and progression of prostate cancer. Eur Urol 2008;53:244–52
- Weisser H, Krieg M. In vitro inhibition of androstenedione 5α-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol 1998;67:49–55
- Liang T, Heiss CE, Cheung AH, et al. 4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor. J Biol Chem 1984;259:734–9
- Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr 2001;9:183–94
- Raynaud JP. Prostate cancer risk in testosterone-treated men. Proceedings of the 17th international symposium of the Journal of Steroid Biochemistry and Molecular Biology. Recent advances in steroid biochemistry and molecular biology; 2006 May 31–Jun 3; Seefeld, Tyrol, Austria; vol. 102
- Vermorken AJM, Goos CMAA, Wirtz P. Evaluation of the hamster flank organ test for the screening of anti-androgens. Br J Dermatol 1982;106:99–101
- Takayasu S, Adachi K. The in vivo and in vitro conversion of testosterone to 17β-hydroxy-5α-androstan-3-one (dihydrotestosterone) by the sebaceous gland of hamsters. Endocrinology 1972;90:73–80
- Takayasu S, Adachi K. The intranuclear binding of 17/3-hydroxy-5α-androstan-3-one and testosterone by hamster sebaceous glands. Endocrinology 1975;96:525–9
- Heck dHA, Casanova M, Starr TB. Formaldehyde toxicit. New understanding. Crit Rev Toxicol 1990;20:397–426